Cytokinetics Inc (CYTK)

NASDAQ
Currency in USD
38.00
+0.19(+0.50%)
Closed·
After Hours
39.19+1.19(+3.13%)
·
CYTK Scorecard
Full Analysis
Suffers from weak gross profit margins
Earnings results expected in 7 days
Fair Value
Day's Range
37.9039.73
52 wk Range
32.7468.44
Key Statistics
Edit
Prev. Close
38
Open
38.6
Day's Range
37.9-39.73
52 wk Range
32.74-68.44
Volume
1.19M
Average Vol. (3m)
1.98M
1-Year Change
-42.05%
Book Value / Share
-1.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYTK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
78.30
Upside
+106.05%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Cytokinetics Inc Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics Inc SWOT Analysis


Market Challenges
Learn about Cytokinetics' strategies to navigate commercialization hurdles, including securing favorable reimbursement and differentiating aficamten in a competitive landscape
Financial Outlook
Analysts project EPS of -$5.38 for FY1 and -$5.13 for FY2, reflecting ongoing R&D investments. Average price target ranges from $78 to $95, indicating growth potential
Pipeline Expansion
Delve into Cytokinetics' robust pipeline, including CK-586 for heart failure and CK-089 for muscular dystrophy, showcasing the company's strategic growth beyond cardiovascula
Aficamten's Promise
Explore Cytokinetics' lead drug candidate aficamten, poised to revolutionize hypertrophic cardiomyopathy treatment with its differentiated profile and market potential
Read full SWOT analysis

Compare CYTK to Peers and Sector

Metrics to compare
CYTK
Peers
Sector
Relationship
P/E Ratio
−7.6x−0.1x−0.5x
PEG Ratio
−2.230.020.00
Price / Book
−33.2x2.4x2.6x
Price / LTM Sales
243.6x12.1x2.9x
Upside (Analyst Target)
96.4%319.6%57.2%
Fair Value Upside
Unlock3.8%8.9%Unlock

Analyst Ratings

18 Buy
3 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 78.30
(+106.05% Upside)

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-1.26 / -1.22
Revenue / Forecast
16.93M / 1.95M
EPS Revisions
Last 90 days

People Also Watch

93.33
BCC
+0.32%
72.2700
SLNO
+1.22%
64.90
WNS
+0.22%
101.20
LNTH
+1.64%

FAQ

What Is the Cytokinetics Inc (CYTK) Stock Price Today?

The Cytokinetics Inc stock price today is 38.00

What Stock Exchange Does Cytokinetics Inc Trade On?

Cytokinetics Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Cytokinetics Inc?

The stock symbol for Cytokinetics Inc is "CYTK."

What Is the Cytokinetics Inc Market Cap?

As of today, Cytokinetics Inc market cap is 4.50B.

What is Cytokinetics Inc Earnings Per Share?

The Cytokinetics Inc EPS is -5.26.

What Is the Next Cytokinetics Inc Earnings Date?

Cytokinetics Inc will release its next earnings report on May 01, 2025.

From a Technical Analysis Perspective, Is CYTK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.